Loading
institutionsInstitution
The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute
Ottawa's academic cancer centre, a world leader in oncolytic viruses (John Bell), the first made-in-Canada CAR-T trial and pragmatic REaCT trials.
Also called: OHRITOH Cancer Centre
Overview
The Ottawa Hospital Cancer Centre and the Ottawa Hospital Research Institute (OHRI) form eastern Ontario's academic cancer programme with the University of Ottawa. John Bell's laboratory is one of the world's leading oncolytic virus groups, developing the Maraba MG1 and vaccinia platforms and co-founding Turnstone Biologics; Rebecca Auer studies perioperative immunotherapy to prevent metastasis after surgery. Natasha Kekre led CLIC-01, the first clinical trial of a CAR-T product manufactured in Canada, and the Rethinking Clinical Trials (REaCT) programme, led by Mark Clemons and Dean Fergusson, embeds pragmatic randomised trials into routine cancer care. The centre also hosts a large radiation oncology and haematology service.
Location
Ottawa, ON, CA
Type
hospital · University of Ottawa
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#321 · 22 points (0 Newsweek + 0 NCI + 22 from 11 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Ottawa Hospital, including child institutions. 494 works · 4,691 citations · 70% open access · 14% clinical trials · 4% reviews.
Oncology works per year
1172022
952023
1072024
1072025
682026
Most works
- Derek J. Jonker32 works
- John Hilton28 works
- Rachel Goodwin27 works
- Dongsheng Tu26 works
- Lisa Vandermeer24 works
- Jonathan M. Loree24 works
- Gregory R. Pond23 works
- Natasha Kekre19 works
- Patricia A. Tang19 works
- Paul Wheatley‐Price19 works
Most cited
- Oncolytic viruses
- Made-in-Canada CAR-T (CLIC-01)
- Pragmatic trials (REaCT)
- Perioperative immunotherapy
John C. Bell
Senior Scientist, Cancer Research Program, Ottawa Hospital Research Institute; University of Ottawa
Oncolytic virotherapyVesicular stomatitis virusVaccinia virus
John Bell's laboratory showed that cancer cells which have broken their interferon alarm cannot defend themselves against a virus, the mechanism the whole field is built on.
Rebecca Auer
Executive Vice-President, Research and Innovation, The Ottawa Hospital / Ottawa Hospital Research Institute
Surgical oncologyPerioperative cancer immunologyOncolytic virus therapy
Cancer surgeon and scientist who leads research and innovation at The Ottawa Hospital and its research institute.
Similar pages
- InstitutionJuravinski Cancer Centre / Escarpment Cancer Research Institute
Shares Ontario Health (Cancer Care Ontario), Canadian Cancer Trials Group (CCTG), Trial design, endpoints and cost, CAR-T cell therapy.
- Key paperStojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either
Shares John C. Bell, Oncolytic viruses.
- IdeaPre-consented cohorts that can be randomised to future trials (TwiCs)
Shares Trials enrol too few, too slowly, Trial design, endpoints and cost, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- Key paperRussell, Peng and Bell 2012: the field states its own problems
Shares John C. Bell, Oncolytic viruses.
- InstitutionCancer Care Alberta (Alberta Health Services)
Shares Canadian Cancer Trials Group (CCTG), Oncolytic viruses, Real-world evidence, HR-positive / HER2-negative breast cancer.
- IdeaPoint-of-care randomisation built into the oncology record
Shares Real-world evidence, Trials enrol too few, too slowly, Trial design, endpoints and cost.
- IdeaRegistry-based randomised trials for oncology comparative effectiveness
Shares Real-world evidence, Trials enrol too few, too slowly, Trial design, endpoints and cost.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Diffuse large B-cell lymphoma.